uPAR-directed ADC / PanTarg - LARVOL DELTA

Unveiling the PanCancer potential of dual-targeting uPAR-directed ADCs across cancers (AACR 2026) - "Moreover, the ADCs showed favorable tolerability consistent with uPAR's restricted expression profile. Overall, these findings validate uPAR as a clinically relevant dual-compartment ADC target and position PanTarg as a promising next-generation therapeutic candidate for PDAC and, more broadly, aggressive uPAR-positive cancers."

ADC • Pan tumor • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor